Lilly bought ImClone Systems Inc. in 2008 in a deal orchestrated by billionaire investor Carl Icahn after an unsolicited, lower bid from Bristol-Myers Squibb Co. Lilly CEO John Lechleiter has said repeatedly the drugmaker isn’t seeking large acquisitions or a combination even with pending patent expirations on several top-selling drugs in the next few years. Lilly spokesman Mark Taylor said the company’s policy is not to comment on market rumors and deal speculation